{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:17:55Z","timestamp":1785460675257,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012330","name":"Okayama University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Infusion-related reaction (IRR) is a common adverse event induced by rituximab. Although first-generation histamine 1 receptor antagonists (H1RAs) are commonly used to prevent IRR, evidence on IRR suppression by the second-generation H1RA bepotastine is scarce. In this study, we assessed the inhibitory effects of bepotastine on rituximab-induced IRR and compared them with those of the first-generation H1RA diphenhydramine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We retrospectively evaluated IRR incidence in patients with B-cell non-Hodgkin lymphoma who received their first dose of rituximab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The incidence of any grade IRR was 9.8% in the bepotastine group (<jats:italic>n<\/jats:italic>\u2009=\u200992), which was significantly lower than the 30.2% rate in the diphenhydramine group (<jats:italic>n<\/jats:italic>\u2009=\u200996; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The incidence of grade 2 or higher IRR was similar between the two groups (6.5% vs. 12.5%; <jats:italic>p<\/jats:italic>\u2009=\u20090.16). Multivariable logistic regression analysis revealed that the risk of any grade IRR incidence was higher in patients with B symptoms and bulky disease. Premedication with bepotastine was an independent factor in reducing the risk of any grade IRR incidence (odds ratio\u2009=\u20090.19, 95% confidence interval: 0.08\u20130.47).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Bepotastine may be more effective than diphenhydramine in reducing the incidence of rituximab-induced IRR, particularly low-grade reactions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12185-025-03990-6","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T15:47:50Z","timestamp":1745941670000},"page":"413-420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative inhibitory effects of bepotastine and diphenhydramine on rituximab-induced infusion reactions"],"prefix":"10.1007","volume":"122","author":[{"given":"Tomoki","family":"Hori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7513-6725","authenticated-orcid":false,"given":"Kazuhiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinako","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Okayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamika","family":"Sudou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moe","family":"Hamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Kitahiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Ikushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuko","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"3990_CR1","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Fo\u00e0 R, Maurer J, O\u2019Brien S, Valente N, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34:2232\u201373.","journal-title":"Adv Ther"},{"key":"3990_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","volume":"13","author":"CH Chung","year":"2008","unstructured":"Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13:725\u201332.","journal-title":"Oncologist"},{"key":"3990_CR3","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","volume":"12","author":"HJ Lenz","year":"2007","unstructured":"Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12:601\u20139.","journal-title":"Oncologist"},{"key":"3990_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1023\/A:1008265313133","volume":"9","author":"K Tobinai","year":"1998","unstructured":"Tobinai K, Kobayashi Y, Narabayashi M, Ogura M, Kagami Y, Morishima Y, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. Ann Oncol. 1998;9:527\u201334.","journal-title":"Ann Oncol"},{"key":"3990_CR5","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/annonc\/mdf155","volume":"13","author":"T Igarashi","year":"2002","unstructured":"Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol. 2002;13:928\u201343.","journal-title":"Ann Oncol"},{"key":"3990_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s11096-021-01348-6","volume":"44","author":"D Tsutsumi","year":"2022","unstructured":"Tsutsumi D, Hayama T, Miura K, Uchiike A, Tsuboi S, Otsuka S, et al. A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma. Int J Clin Pharm. 2022;44:366\u201373.","journal-title":"Int J Clin Pharm"},{"key":"3990_CR7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3904\/kjim.2017.036","volume":"34","author":"KM Cho","year":"2019","unstructured":"Cho KM, Keam B, Ha H, Kim M, Jung JW, Song WJ, et al. Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. Korean J Intern Med. 2019;34:885\u201393.","journal-title":"Korean J Intern Med"},{"key":"3990_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1398-9995.2009.02325.x","volume":"65","author":"MK Church","year":"2010","unstructured":"Church MK, Maurer M, Simons FE, Bindslev-Jensen C, Van Cauwenberge P, Bousquet J, et al. Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy. 2010;65:459\u201366.","journal-title":"Allergy"},{"key":"3990_CR9","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s00198-018-4564-z","volume":"29","author":"H Cho","year":"2018","unstructured":"Cho H, Myung J, Suh HS, Kang HY. Antihistamine use and the risk of injurious falls or fracture in elderly patients: a systematic review and meta-analysis. Osteoporos Int. 2018;29:2163\u201370.","journal-title":"Osteoporos Int"},{"key":"3990_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1046\/j.1365-2125.2001.01471.x","volume":"52","author":"M Tagawa","year":"2001","unstructured":"Tagawa M, Kano M, Okamura N, Higuchi M, Matsuda M, Mizuki Y, et al. Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine. Br J Clin Pharmacol. 2001;52:501\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"3990_CR11","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1038\/cti.2015.14","volume":"4","author":"L Doessegger","year":"2015","unstructured":"Doessegger L, Banholzer ML. Clinical development methodology for infusion-related reactions with monoclonal antibodies. Clin Transl Immunology. 2015;4:e39.","journal-title":"Clin Transl Immunology"},{"key":"3990_CR12","unstructured":"U.S. Food and Drug Administration. U.S. Food & Drug Administration. Drugs @FDA: FDA-Approved Drugs. rituximab drug label. Accessed July 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103705s5467lbl.pdf [Internet]. 2021. Available from: www.fda.gov\/medwatch. Accessed 30 July 2024."},{"key":"3990_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s11096-017-0429-3","volume":"39","author":"T Hayama","year":"2017","unstructured":"Hayama T, Miura K, Uchiike A, Nakagawa M, Tsutsumi D, Sakagami M, et al. A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas. Int J Clin Pharm. 2017;39:380\u20135.","journal-title":"Int J Clin Pharm"},{"key":"3990_CR14","first-page":"1145","volume":"21","author":"J Hong","year":"2013","unstructured":"Hong J, Kim JY, Ahn HK, Lee SM, Sym SJ, Park J, et al. Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma. Support Care Cancer. 2013;21:1145\u201352.","journal-title":"Support Care Cancer"},{"key":"3990_CR15","doi-asserted-by":"publisher","first-page":"3688727","DOI":"10.1155\/2022\/3688727","volume":"2022","author":"S Ohata","year":"2022","unstructured":"Ohata S, Takenaka K, Sugiyama D, Sugimoto T. Bone marrow infiltration is a distinctive risk factor for rituximab infusion-related reactions in CD20-positive B-cell non-Hodgkin lymphoma. Adv Hematol. 2022;2022:3688727.","journal-title":"Adv Hematol"},{"key":"3990_CR16","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1177\/1078155218811505","volume":"25","author":"CG Durham","year":"2019","unstructured":"Durham CG, Thotakura D, Sager L, Foster J, Herrington JD. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions. J Oncol Pharm Pract. 2019;25:1396\u2013401.","journal-title":"J Oncol Pharm Pract"},{"key":"3990_CR17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.5649\/jjphcs.45.396","volume":"45","author":"N Matsui","year":"2019","unstructured":"Matsui N, Ishihara N, Mochizuki Y, Tamaki H, Nishimura N, Naora K. Inhibitory effect on rituximab-induced infusion reaction by premedication with fexofenadine or Bepotastine. Jpn J Pharm Health Care Sci. 2019;45:396\u2013403.","journal-title":"Jpn J Pharm Health Care Sci"},{"key":"3990_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/1744666X.2019.1562905","volume":"15","author":"F Paul","year":"2019","unstructured":"Paul F, Cartron G. Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol. 2019;15:383\u20139.","journal-title":"Expert Rev Clin Immunol"},{"key":"3990_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000336839","volume":"159","author":"A Vultaggio","year":"2012","unstructured":"Vultaggio A, Matucci A, Nencini F, Pratesi S, Petroni G, Cammelli D, et al. Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab. Int Arch Allergy Immunol. 2012;159:321\u20136.","journal-title":"Int Arch Allergy Immunol"},{"key":"3990_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.imlet.2007.07.010","volume":"113","author":"K Bloemen","year":"2007","unstructured":"Bloemen K, Verstraelen S, Van Den Heuvel R, Witters H, Nelissen I, Schoeters G. The allergic cascade: review of the most important molecules in the asthmatic lung. Immunol Lett. 2007;113:6\u201318.","journal-title":"Immunol Lett"},{"key":"3990_CR21","doi-asserted-by":"publisher","first-page":"S763","DOI":"10.1016\/S0091-6749(97)70125-8","volume":"99","author":"JN Baraniuk","year":"1997","unstructured":"Baraniuk JN. Pathogenesis of allergic rhinitis. J Allergy Clin Immunol. 1997;99:S763\u201372.","journal-title":"J Allergy Clin Immunol"},{"key":"3990_CR22","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1185\/03007995.2010.486753","volume":"26","author":"JI Williams","year":"2010","unstructured":"Williams JI, Gow JA, Klier SM, McCue SL, Salapatek AM, McNamara TR. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine Bepotastine besilate. Curr Med Res Opin [Internet]. 2010;26:2329\u201338.","journal-title":"Curr Med Res Opin [Internet]"},{"key":"3990_CR23","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","volume":"94","author":"U Winkler","year":"1999","unstructured":"Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217\u201324.","journal-title":"Blood"},{"key":"3990_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000330663","volume":"158","author":"H Tanizaki","year":"2012","unstructured":"Tanizaki H, Ikoma A, Fukuoka M, Miyachi Y, Kabashima K. Effects of bepotastine and fexofenadine on histamine-induced flare, wheal and itch. Int Arch Allergy Immunol. 2012;158:191\u20135.","journal-title":"Int Arch Allergy Immunol"},{"key":"3990_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3390\/pharmaceutics16030334","volume":"16","author":"S Yoon","year":"2024","unstructured":"Yoon S, Jin BH, Kim CO, Park K, Park MS, Chae D. Pharmacokinetic modeling of Bepotastine for determination of optimal dosage regimen in pediatric patients with allergic rhinitis or urticaria. Pharmaceutics. 2024;16:334.","journal-title":"Pharmaceutics"},{"key":"3990_CR26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/cpdd.391","volume":"7","author":"CK Gelotte","year":"2018","unstructured":"Gelotte CK, Zimmerman BA, Thompson GA. Single-dose pharmacokinetic study of diphenhydramine HCl in children and adolescents. Clin Pharmacol Drug Dev. 2018;7:400\u20137.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"3990_CR27","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/j.1552-4604.1990.tb01871.x","volume":"30","author":"KJ Simons","year":"1990","unstructured":"Simons KJ, Watson WT, Martin TJ, Chen XY, Simons FE. Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. J Clin Pharmacol. 1990;30:665\u201371.","journal-title":"J Clin Pharmacol"},{"key":"3990_CR28","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1111\/jcpt.13799","volume":"47","author":"L Yang","year":"2022","unstructured":"Yang L, Zheng Z, Li N, Zheng B, Liu M, Cai H. Efficacy and safety of rituximab biosimilars or reference product as first-line treatment in patients with low-tumour-burden follicular lymphoma: a systematic review and meta-analysis. J Clin Pharm Ther. 2022;47:1923\u201331.","journal-title":"J Clin Pharm Ther"},{"key":"3990_CR29","doi-asserted-by":"publisher","first-page":"e54882","DOI":"10.2196\/54882","volume":"13","author":"Y Kitahiro","year":"2024","unstructured":"Kitahiro Y, Yamamoto K, Yakushijin K, Ioroi T, Tanda M, Itohara K, et al. The efficacy of Bepotastine besilate compared with hydroxyzine pamoate for preventing infusion reactions to the first dose of rituximab in patients with non-Hodgkin lymphoma: protocol for a Phase II, double-blind, multicenter randomized trial. JMIR Res Protoc. 2024;13:e54882.","journal-title":"JMIR Res Protoc"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03990-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03990-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03990-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:35:50Z","timestamp":1757162150000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03990-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3990"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03990-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study conformed to the provisions of the Declaration of Helsinki. The Institutional Review Board of Nara Prefecture General Medical Center approved the study protocol (Approval No.763).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"A summary of the study and consent to publication was declared available so that each participant could refuse to participate in the study at any time.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}